Susoctocog alfa, Recombinant porcine BDD antihaemophilic factor VIII (FVIII)
Recombinant, B-domain deleted, porcine sequence antihaemophilic factor VIII (FVIII) is a glycoprotein containing a 90 kDa heavy chain and a 80 kDa light chain with the naturally-occuring B domain replaced with a twenty-four amino acid linker.
170000.0 Da (Approximate, B-Domain deleted)
>99% by SDS-Page and HPLC analysis
<0.001 EU per 1 μg by the LAL method
Indicated for the treatment of bleeding episodes in adults with acquired hemophilia A.
Examples of Clinical Use:
Acquired hemophilia A
Following the product administration, the activated partial thromboplastin time (aPTT) is expected to normalize indicating restored biological activity of factor VIII and normal clotting time. In a prospective, open-label clinical trail involving 28 subjects with acquired haemophilia A, all subjects had a positive response to treatment for the initial bleeding episodes at 24 hours after dosing where bleeding was either stopped or substantially reduced.
Mechanism of action:
Factor VIII circulates in the plasma as a hemostatically active protein complex that consists of factor VIII and a large carrier protein von Willebrand factor via a non-covalent binding interaction. This protein complex remains inactive until the coagulation cascade is activated which in turn activates factor VIII to be released from factor VIII/von Willebrand factor complex. Activated factor VIII acts as a cofactor for factor IX-mediated conversion of factor X to activated factor X. Activated factor X is critical in converting prothrombin into thrombin and sequentially, thrombin converts fibrinogen to fibrin for the formation of a blood clot.
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.